Literature DB >> 18772291

Outcomes from treatment of infertility with natural procreative technology in an Irish general practice.

Joseph B Stanford1, Tracey A Parnell, Phil C Boyle.   

Abstract

OBJECTIVES: We evaluated outcomes in couples treated for infertility with natural procreative technology (NaProTechnology [corrected] NPT), a systematic medical approach for optimizing physiologic conditions for conception in vivo, from an Irish general practice.
METHODS: All couples receiving treatment from 2 NPT-trained family physicians between February 1998 and January 2002 were studied. The main outcome was live birth, and secondary outcomes included conceptions and multiple births. Crude proportions and adjusted life-table proportions were calculated per 100 couples.
RESULTS: A total of 1239 couples had an initial consult for NPT, of which 1072 had been trying for at least a year to conceive and initiated treatment. The average female age was 35.8 years, the mean duration of attempting to conceive was 5.6 years, 24% had a prior birth, and 33% had previously attempted treatment with assisted reproductive technology (ART). All couples were taught to identify the fertile days of the menstrual cycle with the Creighton Model FertilityCare System, and most received additional medical treatment, including clomiphene (75%). In life-table analysis, the cumulative proportion of first live births for those completing up to 24 months of NPT treatment was 52.8 per 100 couples. The crude proportion was 25.5. Younger couples and couples without previous ART attempts had higher rates of live birth. Among live births, there were 4.6% twin births.
CONCLUSION: NPT provided by trained general practitioners had live birth rates comparable to cohort studies of more invasive treatments, including ART. Further studies are warranted to compare NPT directly to other treatments.

Entities:  

Mesh:

Year:  2008        PMID: 18772291     DOI: 10.3122/jabfm.2008.05.070239

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  16 in total

1.  Natural procreative technology for infertility and recurrent miscarriage: outcomes in a Canadian family practice.

Authors:  Elizabeth Tham; Karen Schliep; Joseph Stanford
Journal:  Can Fam Physician       Date:  2012-05       Impact factor: 3.275

2.  NFP and NaProTechnology.

Authors:  Helen Watt
Journal:  Linacre Q       Date:  2013-02

3.  How Humanae vitae has advanced reproductive health.

Authors:  Derek M Doroski
Journal:  Linacre Q       Date:  2014-08

4.  Maternity After Orthotopic Liver Transplantation: Can the Use of Biological Fertility Indicators Help? Our Own Experience and Literature-based Recommendations.

Authors:  Antonio Castillo; María Eugenia Huete; Tania Errasti; Guillermo Pérez de Lema
Journal:  Linacre Q       Date:  2022-01-10

Review 5.  Fertility Awareness-Based Methods for Women's Health and Family Planning.

Authors:  Marguerite Duane; Joseph B Stanford; Christina A Porucznik; Pilar Vigil
Journal:  Front Med (Lausanne)       Date:  2022-05-24

6.  Epigenetic regulatory mechanisms associated with infertility.

Authors:  Sheroy Minocherhomji; Prochi F Madon; Firuza R Parikh
Journal:  Obstet Gynecol Int       Date:  2010-08-05

7.  Developments in IVF legislation in a Catholic country.

Authors:  Pierre Mallia
Journal:  Med Health Care Philos       Date:  2013-08

8.  Population, Reproductive, and Sexual Health: Data Are Essential Where Disciplines Meet and Ideologies Conflict.

Authors:  Joseph B Stanford
Journal:  Front Public Health       Date:  2016-03-07

9.  Medical Students' Knowledge of Fertility Awareness-Based Methods of Family Planning.

Authors:  Peter G Danis; Sally A Kurz; Laura M Covert
Journal:  Front Med (Lausanne)       Date:  2017-06-01

10.  Restorative reproductive medicine for infertility in two family medicine clinics in New England, an observational study.

Authors:  Joseph B Stanford; Paul A Carpentier; Barbara L Meier; Mark Rollo; Benjamin Tingey
Journal:  BMC Pregnancy Childbirth       Date:  2021-07-07       Impact factor: 3.007

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.